Bifidobacterium bifidum BCMC 02290 (B. bifidum BCMC 02290)

Bifidobacterium bifidum BCMC 02290 is a specific probiotic bacterial strain that resides as a commensal organism in the human gastrointestinal tract [9, 14]. It is a core component of clinical-grade multi-strain probiotic formulations (such as Hexbio) used to treat dysbiosis and associated metabolic or inflammatory conditions [1, 11]. The strain facilitates gut health by colonizing the intestinal wall, where it competes with pathogenic bacteria for nutrients and adhesion sites, thereby preventing infections and maintaining the integrity of the epithelial barrier [4, 6]. Metabolically, BCMC 02290 ferments complex carbohydrates to produce beneficial short-chain fatty acids (SCFAs) like acetate and lactate, which nourish colonocytes and regulate the gut pH [2, 13]. Clinical research indicates that its administration can alleviate symptoms of irritable bowel syndrome (IBS), support immune function, and reduce systemic inflammation in patients with non-alcoholic fatty liver disease (NAFLD) [1, 11, 12]. As a live biological agent rather than a single protein or receptor, it represents a microbiome-based therapeutic intervention rather than a traditional molecular drug target [18, 20].

Other names

B. bifidum BCMC 02290BCMC 02290Bifidobacterium bifidum BCMC 02290

The strain acts through competitive exclusion of pathogens, synthesis of short-chain fatty acids (SCFAs), enhancement of intestinal barrier function via tight junction protein regulation, and modulation of host immune signaling by reducing pro-inflammatory cytokines.